Pharsight

Triumeq patents expiration

TRIUMEQ's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5905082 VIIV HLTHCARE Crystalline oxathiolane derivatives
May, 2016

(8 years ago)

US6294540 VIIV HLTHCARE Carbocyclic nucleoside hemisulfate and its use in treating viral infections
May, 2018

(6 years ago)

US8129385 VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Oct, 2027

(3 years from now)

US9242986 VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Dec, 2029

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6417191 VIIV HLTHCARE Synergistic combinations of zidovudine, 1592U89 and 3TC
Mar, 2016

(8 years ago)

US6417191

(Pediatric)

VIIV HLTHCARE Synergistic combinations of zidovudine, 1592U89 and 3TC
Sep, 2016

(7 years ago)

US5905082

(Pediatric)

VIIV HLTHCARE Crystalline oxathiolane derivatives
Nov, 2016

(7 years ago)

US6294540

(Pediatric)

VIIV HLTHCARE Carbocyclic nucleoside hemisulfate and its use in treating viral infections
Nov, 2018

(5 years ago)

US8129385

(Pediatric)

VIIV HLTHCARE Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness
Apr, 2028

(3 years from now)

US9242986

(Pediatric)

VIIV HLTHCARE Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates
Jun, 2030

(6 years from now)

Triumeq is owned by Viiv Hlthcare.

Triumeq contains Abacavir Sulfate; Dolutegravir Sodium; Lamivudine.

Triumeq has a total of 10 drug patents out of which 6 drug patents have expired.

Expired drug patents of Triumeq are:

  • US6417191
  • US6417191*PED
  • US5905082*PED
  • US6294540*PED
  • US5905082
  • US6294540

Triumeq was authorised for market use on 22 August, 2014.

Triumeq is available in tablet;oral dosage forms.

Triumeq can be used as treatment of human immunodeficiency virus (hiv) infection..

Drug patent challenges can be filed against Triumeq from 15 December, 2025.

The generics of Triumeq are possible to be released after 08 June, 2030.

Drug Exclusivity Drug Exclusivity Expiration
M(M-294) Jun 15, 2026
Pediatric Exclusivity(PED) Dec 15, 2026
New Chemical Entity Exclusivity(NCE) Aug 12, 2018
New Dosing Schedule(D-147) Mar 23, 2018

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE ingredient

NCE-1 date: 15 December, 2025

Market Authorisation Date: 22 August, 2014

Treatment: Treatment of human immunodeficiency virus (hiv) infection.

Dosage: TABLET;ORAL

How can I launch a generic of TRIUMEQ before it's drug patent expiration?
More Information on Dosage

TRIUMEQ family patents

Family Patents